Minimally Manipulated Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Systematic Review of Clinical Evidence.
Journal
Stem cells international
ISSN: 1687-966X
Titre abrégé: Stem Cells Int
Pays: United States
ID NLM: 101535822
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
01
2019
accepted:
21
07
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
6
9
2019
Statut:
epublish
Résumé
The use of laboratory-expanded mesenchymal stem cells (MSCs) is subject to several restrictions, resulting in "minimal manipulation" methods becoming the current most popular strategy to increase the use of MSCs in an orthopaedic practice. The aim of the present systematic review is to assess the clinical applications of "minimally" manipulated MSCs, either as bone marrow aspirate concentrate (BMAC) or as stromal vascular fraction (SVF), in the treatment of knee osteoarthritis (OA). A systematic review of three databases (PubMed, ScienceDirect, and Google Scholar) was performed using the following keywords: "Knee Osteoarthritis" with "(Bone marrow aspirate) OR (bone marrow concentrate)" or with "(adipose-derived mesenchymal stem cells) OR (adipose derived stromal cells) OR (stromal vascular fraction) OR (SVF)" as either keywords or MeSH terms. The reference lists of all retrieved articles were further reviewed for identification of potentially relevant studies. Twenty-three papers were included in the final analysis (10 on BMAC and 13 on SVF). Of these, only 4 were randomized controlled trials (RCTs). Bias risk evaluation, performed using a modified Coleman score, revealed an overall poor quality of the studies. In terms of clinical application, despite the apparent safety of minimally manipulated MSCs and the short-term positive clinical outcomes associated with their use, clinicians reported different preparation and administration methods, ranging from single intra-articular injections to intraosseous applications to administration in combination with other surgical procedures. The available literature is undermined by both the lack of high-quality studies and the varied clinical settings and different protocols reported in the few RCTs presently published. This prevents any recommendation on the use of either product in a clinical practice. Nevertheless, the use of minimally manipulated MSCs (in the form of BMAC or SVF) has been shown to be safe and have some short-term beneficial effects.
Sections du résumé
BACKGROUND
BACKGROUND
The use of laboratory-expanded mesenchymal stem cells (MSCs) is subject to several restrictions, resulting in "minimal manipulation" methods becoming the current most popular strategy to increase the use of MSCs in an orthopaedic practice. The aim of the present systematic review is to assess the clinical applications of "minimally" manipulated MSCs, either as bone marrow aspirate concentrate (BMAC) or as stromal vascular fraction (SVF), in the treatment of knee osteoarthritis (OA).
METHODS
METHODS
A systematic review of three databases (PubMed, ScienceDirect, and Google Scholar) was performed using the following keywords: "Knee Osteoarthritis" with "(Bone marrow aspirate) OR (bone marrow concentrate)" or with "(adipose-derived mesenchymal stem cells) OR (adipose derived stromal cells) OR (stromal vascular fraction) OR (SVF)" as either keywords or MeSH terms. The reference lists of all retrieved articles were further reviewed for identification of potentially relevant studies.
RESULTS
RESULTS
Twenty-three papers were included in the final analysis (10 on BMAC and 13 on SVF). Of these, only 4 were randomized controlled trials (RCTs). Bias risk evaluation, performed using a modified Coleman score, revealed an overall poor quality of the studies. In terms of clinical application, despite the apparent safety of minimally manipulated MSCs and the short-term positive clinical outcomes associated with their use, clinicians reported different preparation and administration methods, ranging from single intra-articular injections to intraosseous applications to administration in combination with other surgical procedures.
CONCLUSIONS
CONCLUSIONS
The available literature is undermined by both the lack of high-quality studies and the varied clinical settings and different protocols reported in the few RCTs presently published. This prevents any recommendation on the use of either product in a clinical practice. Nevertheless, the use of minimally manipulated MSCs (in the form of BMAC or SVF) has been shown to be safe and have some short-term beneficial effects.
Identifiants
pubmed: 31485234
doi: 10.1155/2019/1735242
pmc: PMC6710724
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1735242Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Mol Biol Cell. 2002 Dec;13(12):4279-95
pubmed: 12475952
J Bone Joint Surg Am. 2003;85-A Suppl 2:40-4
pubmed: 12721344
Cytotherapy. 2004;6(1):7-14
pubmed: 14985162
J Cell Physiol. 2006 Jul;208(1):64-76
pubmed: 16557516
Cytotherapy. 2006;8(2):166-77
pubmed: 16698690
Circ Res. 2007 May 11;100(9):1249-60
pubmed: 17495232
J Cell Physiol. 2007 Nov;213(2):341-7
pubmed: 17620285
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Am J Sports Med. 2009 Nov;37 Suppl 1:156S-66S
pubmed: 19861700
Knee Surg Sports Traumatol Arthrosc. 2012 Mar;20(3):423-35
pubmed: 22173730
J Cell Physiol. 2013 May;228(5):938-44
pubmed: 23042088
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Knee Surg Sports Traumatol Arthrosc. 2013 Aug;21(8):1717-29
pubmed: 23306713
Arthroscopy. 2013 Apr;29(4):748-55
pubmed: 23375182
Front Immunol. 2013 Sep 04;4:201
pubmed: 24027567
Knee Surg Sports Traumatol Arthrosc. 2015 May;23(5):1308-16
pubmed: 24326779
Eur J Orthop Surg Traumatol. 2014 Dec;24(8):1505-11
pubmed: 24398701
Am J Sports Med. 2014 Jul;42(7):1628-37
pubmed: 24743139
Arthroscopy. 2014 Nov;30(11):1453-60
pubmed: 25108907
Biomed Res Int. 2014;2014:370621
pubmed: 25276781
Am J Sports Med. 2015 Jan;43(1):176-85
pubmed: 25349263
BMC Musculoskelet Disord. 2015 Sep 18;16:258
pubmed: 26385099
Phys Sportsmed. 2016;44(2):101-8
pubmed: 26985986
Knee Surg Sports Traumatol Arthrosc. 2016 Jun;24(6):1826-35
pubmed: 27120191
Regen Med. 2016 Sep;11(6):511-20
pubmed: 27527808
Stem Cells Transl Med. 2017 Jan;6(1):187-195
pubmed: 28170179
J Transl Med. 2017 Jun 19;15(1):141
pubmed: 28629466
Genes (Basel). 2017 Oct 13;8(10):null
pubmed: 29027984
Int Orthop. 2018 Nov;42(11):2563-2571
pubmed: 29589086
J Stem Cell Res (Overl Park). 2017;1(3):1-10
pubmed: 29721552
PM R. 2018 Dec;10(12):1353-1359
pubmed: 29857166
Clin Med Insights Arthritis Musculoskelet Disord. 2018 Jun 18;11:1179544118781080
pubmed: 29977117
Int J Mol Sci. 2018 Jul 23;19(7):null
pubmed: 30041472
Int Orthop. 2019 May;43(5):1123-1134
pubmed: 30109404
Cartilage. 2018 Aug 30;:1947603518796142
pubmed: 30160168
Int Orthop. 2019 Mar;43(3):751-752
pubmed: 30187097
Stem Cells Transl Med. 2018 Dec;7(12):876-886
pubmed: 30255987
Regen Ther. 2017 May 19;6:108-112
pubmed: 30271845
Int Orthop. 2019 Jan;43(1):15-23
pubmed: 30311059
BMC Musculoskelet Disord. 2018 Oct 24;19(1):383
pubmed: 30355323
Heliyon. 2018 Oct 18;4(10):e00871
pubmed: 30364761
Arthroscopy. 2019 Jan;35(1):251-259
pubmed: 30455088
Arthroscopy. 2019 Jan;35(1):260-261
pubmed: 30611357